Take Action
Research Details
Bayer & Millennium Pharmaceuticals
Abstract
In the year 2000 Millennium Pharmaceuticals was the poster child for successful genomic companies. Millennium's fast growth and exuberant valuations were due to the elegant alliances the company had forged with top pharmaceutical, biotechnology, and agricultural companies. However as the market shifted and Millennium was forced to fully integrate, the type and structure of its alliances no longer worked. This case illustrates how strategic alliances are used in biotechnology as growth tools and demonstrates the impact that market conditions can have on the evolution of alliances.
Type
Case
Author(s)
Alicia Loffler, Markus Solf, Edward Zajac
Date Published
01/01/2004
Discipline
Biotechnology;Management;Organizational Behavior;Strategy
Key Concepts
Biotechnology, Alliances, Business Model Change, Strategic Alliances, Product Development, Valuation, Management Strategy, Growth Strategy
Citations
Loffler, Alicia, Markus Solf, and Edward Zajac. Bayer & Millennium Pharmaceuticals. Case 5-104-014 (KEL068).
PREVIEW or BUY